
Name of the Issue: Sai Life Sciences Limited

- 1 **Type of Issue** Initial Public Offer
- 2 **Issue Size (Rs. Mn)** 30,426.20*

**Source: As per the prospectus*

3 **Grade of issue along with name of the rating agency**

Name Not Applicable
Grade Not Applicable

4 **Subscription Level (Number of times)** 7.50

**The above figure is after technical rejection and excludes anchor allotment*

Source: Basis of allotment

5 **QIB Holding (as a % of Outstanding Capital) as disclosed to the stock exchanges**

Particulars	%
(i) On Allotment *	13.25
(ii) at the end of the Quarter immediately after the listing of the issue (December 31, 2024)	7.08%
(iii) at the end of 1st FY (March 31, 2025)	25.62%
(iv) at the end of 2nd FY (March 31, 2026)**	N.A.
(v) at the end of 3rd FY (March 31, 2027)**	N.A.

**Shareholding pattern disclosed to Stock Exchanges*

*** QIB Holding not disclosed as reporting for relevant period has not been completed.*

6 **Financials of the issuer**

(Rs. Crores)

Parameters	1st FY (March 31, 2025)	2nd FY (March 31, 2026) *	3rd FY (March 31, 2027) *
Income from operations	1,642.05	Not Available	Not Available
Net Profit for the period	173.46	Not Available	Not Available
Paid-up equity share capital	20.84	Not Available	Not Available
Reserves excluding revaluation reserves	2,146.62	Not Available	Not Available

** Financials not available as reporting for the relevant years has not been completed.*

7 Trading Status

The equity shares of the Company are listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")
The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2026) *	Not Available
(iii) at the end of 3rd FY (March 31, 2027) *	Not Available

* Trading status not disclosed as the relevant fiscal years have not been completed.

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2025)	Mitesh Daga Dinesh V Patel Rajagopal Srirama Tatta	Resigned Appointed Cessation
(ii) at the end of 2nd FY (March 31, 2026) *	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2027) *	Not Available	Not Available

* Changes in Directors of Issuer not updated as the relevant financial years have not been completed

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document	(i) Repayment/ prepayment, in full or part, of all or certain outstanding borrowings availed by our Company (INR 7,200.00 mn)
	(ii) General corporate purposes(INR 1,898.84 mn)
(ii) Actual utilization	(i) Repayment/ prepayment, in full or part, of all or certain outstanding borrowings availed by our Company (INR 7,200.00 mn) - completed
	(ii) General corporate purposes(INR 1,898.84 mn) - INR 935.81 mn utilized, balance INR 963.03 mn to be utilized
(iii) Reasons for deviation, if any	NA*

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange NSE
Issue Price (Rs.) 549.00
Listing Date 18-Dec-24

Price parameters	At close of listing day- 13- Nov-24	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2025)		
				Closing price	High	Low
Market Price	765.80	716.85	704.85	760.85	783.00	750.70
NIFTY 50	24,201.20	23,311.80	22,508.75	23,519.35	23,649.20	23,450.20
Sectoral Index (NSE - Healthcare Index)	13,912.40	13,997.10	13,273.35	13,681.30	15,108.80	11,325.00

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2026)*			As at the end of the 3rd FY after the listing of the issue (31st March, 2027)*		
	Closing price	High	Low	Closing price	High	Low
Market Price	Not available*	Not available*	Not available*	Not available*	Not available*	Not available*
NIFTY 50	Not available*	Not available*	Not available*	Not available*	Not available*	Not available*
Sectoral Index (NSE - Healthcare Index)	Not available*	Not available*	Not available*	Not available*	Not available*	Not available*

* The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio	As disclosed in the Prospectus	At the end of 1st FY (March 31, 2025)	At the end of 1st FY (March 31, 2026)***	At the end of 1st FY (March 31, 2027)***
EPS (Basic)	Company*	4.53	9.00	Not Available
	Peer Group & Industry Avg**	28.26	29.17	Not Available
	Divi's Laboratories Limited	60.27	82.53	Not Available
	Suven Pharmaceuticals Limited	11.80	-7.37	Not Available
	Syngene International Limited	12.71	12.35	
EPS (Diluted)	Company*	4.57	8.78	Not Available
	Peer Group & Industry Avg**	28.25	29.17	Not Available
	Divi's Laboratories Limited	60.27	82.53	Not Available
	Suven Pharmaceuticals Limited	11.80	-7.37	Not Available
	Syngene International Limited	12.69	12.34	Not Available
P/E	Company*	121.19	86.66	Not Available
	Peer Group & Industry Avg**	96.00	61.34	Not Available
	Divi's Laboratories Limited	103.04	69.98	Not Available
	Suven Pharmaceuticals Limited	109.37	NA	Not Available
	Syngene International Limited	75.59	52.69	Not Available

RONW	Company*	8.50%	8.00%	Not Available	Not Available
	Peer Group & Industry Avg**	12.80%	12.57%	Not Available	Not Available
	Divi's Laboratories Limited	11.79%	14.64%	Not Available	Not Available
	Suven Pharmaceuticals Limited	14.64%	NA	Not Available	Not Available
	Syngene International Limited	11.98%	10.50%	Not Available	Not Available
NAV per share	Company*	53.83	104.00	Not Available	Not Available
	Peer Group & Industry Avg**	237.05	341.15	Not Available	Not Available
	Divi's Laboratories Limited	511.21	564.87	Not Available	Not Available
	Suven Pharmaceuticals Limited	94.04	NA	Not Available	Not Available
	Syngene International Limited	105.91	117.44	Not Available	Not Available

* Sourced from Prospectus dated December 13, 2024

**All the financial information for listed industry peers is on a consolidated basis and is sourced from the financial information of such listed industry peer as at and for the year ended March 31, 2024. March 31, 2025 available on the website of the stock exchanges or the Company

***Data for relevant period not yet published

Notes

1. Basic and diluted earnings/ (loss) per equity share: Basic and diluted earnings/ (loss) per equity share are computed in accordance with Indian Accounting Standard 33 notified under the Companies (Indian Accounting Standards) Rules of 2015 (as amended).

2. Net Asset Value per share = Restated equity attributable to owners of our Company / total number of equity shares outstanding during the period.

3. Return on Net Worth (%) = Restated net profit/(loss) after tax for the years/period attributable to the owners of our Company / by the Net worth as on the last date of the respective period

14 Any other material information

Particulars	Date
Order dated 12th November, 2025 was passed by the Assistant Commissioner, Central Tax, Division-II (Pimpri), Pune-I Commissionerate u/s 74 of the CGST Act, 2017. Order passed under Section 74 of the Goods and Services Tax Act, 2017,	13-Nov-25
Monitoring agency report published	12-Nov-25
Company has announced plans to recruit 200 scientists in November 2025 to meet the increasing demand for its Discovery and CMC services.	11-Nov-25
Board of Directors of the Company has approved and allotted 19,995 and 2,29,974 fully paid-up equity shares of Re.1/ each upon exercise of options granted under ESOP 2008 and MESOP 2018 respectively	4-Nov-25
Company along with Agility Life Sciences and Centrix Pharma Solutions, has announced the launch of an Integrated CMC Partnership aimed at accelerating drug development for innovator biopharma companies.	8-Oct-25
Company has successfully opened Unit VI, a dedicated facility for veterinary API production, in Bidar, India, located alongside Unit IV, the company's flagship API manufacturing site in Bidar, Karnataka, India ("Unit IV Bidar Facility")	18-Sep-25
Company appointed M/s. P S Rao & Associates, Practicing Company Secretaries as the Secretarial Auditor of the Company for a term of (five) consecutive financial years commencing from the financial year 2025-26 to 2029-30.	11-Sep-25
Monitoring Agency Report for the quarter ended 30 June 2025 in relation to the Initial Public Offer (IPO) of the Company.	13-Aug-25
Company has approved and allotted 3,00,000 fully paid-up equity shares of Re.1/- each upon exercise of options granted under MESOP 2018	23-Jul-25
Company has approved and allotted 40,403 fully paid-up equity shares of Re.1/- each upon exercise of options granted under MESOP 2018	27-Jun-25
Revision in intimation under Regulation 30 of LODR dated 23rd May 2025 and 09th June 2025 with respect to the allotment of Equity Shares on exercise of Employee Stock Options ("ESOPs").	27-Jun-25
Commencement Of Commercial Operation Of The Second Phase Of The Production - (Unit IV Bidar Facility)	20-JUN-205
Ratification Of ESOP Scheme And Extension Of Benefits To The Employees Of Its Subsidiaries.	17-Jun-25
Appointment of Mr. Sivaramakrishnan Chittor, (DIN: 01092158) as Whole-Time Director of the Company	17-Jun-25
Appointment of Dr. Dinesh V Patel (DIN- 11010657) to the office of Independent Director	17-Jun-25
Company allotted 14,000 fully paid-up equity shares of Re.1/ each upon exercise of options granted under ESOP 2018 and 5,000 fully paid-up equity shares of Re.1/ each upon exercise of options granted under ESOP 2008.	9-Jun-25
Monitoring agency report shared with the stock exchanges	14-May-25
Appointment of Ms P S Rao and Associates as Secretarial Auditors of the company w.e.f. May 13, 2025 subject to the approval of members in the ensuing AGM	14-May-25
Board of Directors of the Company has approved the appointment of Mr. Sivaramakrishnan Chittor, (DIN: 01092158) as an Additional Director of the Company.	28-Apr-25

Change in Sauri Gudlavalleti, who held the position of Chief Operating Officer, will move into the new role of Head of Special Projects with effect from the close of business on 23 April, 2025.	23-Apr-25
Setting up of new Peptide research centre in India	3-Apr-25
Appointment of new independent director - Dinesh v Patel and cessation of Rajagopal Srirama Tatta	24-Mar-25
Company informed the Exchange regarding 'Reporting of violation under the Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives of the Company (the Code) under SEBI (Prohibition of Insider Trading) Regulations, 2015	20-Mar-25
Company informed the exchange that an Order was passed by the Joint Commissioner of State Tax, Pune, Maharashtra on 28 February 2025 (received on 11 March 2025 6:44 IST) , rejecting the refund claim of input VAT and CST credit under the Maharashtra Value Added Tax Act, 2002 and the Central Sales Tax Act, 1956.	12-Mar-25
Resignation of Mitesh Daga as Non- Executive Director of the company w.e.f. March 10, 2025	10-Mar-25
Order was passed by the Joint Commissioner (ST) Malkajgiri Division, Hyderabad, Telangana on 28 February 2025, raising a demand on the Company.	1-Mar-25
Monitoring agency report shared with the stock exchanges	10-Feb-25
The Company has entered into a long-term lease agreement for acquiring an area of 1.21 acres of land along with certain building structures in Shamirpet, Hyderabad at an upfront investment of approximately Rs. 15 Crs.	25-Jan-25

Note: For further updates and information, please refer Stock Exchange websites